Drugs / Etripamil
Etripamil
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed paroxysmal atrial fibrillation 2 milestones | |||||
| Filed | EU (EMA) | TACHYMIST | paroxysmal atrial fibrillation | 2026-01-06 | “today announced the acceptance of a Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) seeking the approval of etripamil nasal spray” milestonepharma.com ↗ |
| Filed | China (NMPA) | — | paroxysmal atrial fibrillation | 2025-01-17 | “In China, the New Drug Application (NDA) for etripamil nasal spray was accepted by the National Medical Products Administration (NMPA) on January 17, 2025.” milestonepharma.com ↗ “The New Drug Application for etripamil for PSVT in China is currently under review by China’s National Medical Products Administration (NMPA).” milestonepharma.com ↗ |
| Approved Indication not stated 1 milestone | |||||
| Approved | US (FDA) | CARDAMYST | — | 2025-12-12 | fda.gov ↗ |
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05511870 | Mar 2023 | — | Corxel Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials · 2 met primary | ||||||
| Phase 2 | NCT05763953 | Dec 2023 → Jun 2027 expected | cardiac rhythm disease | Milestone Pharmaceuticals Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT04467905 | Nov 2020 → Aug 2023 | atrial fibrillation | Milestone Pharmaceuticals Inc. | Completed | Met primary |
| Phase 2 | NCT02296190 | Mar 2015 → Dec 2016 | cardiac rhythm disease | Milestone Pharmaceuticals Inc. | Completed | Met primary |
| Phase 36 trials | ||||||
| Phase 3 | NCT06716021 | Jan 2027 → Jan 2029 expected | atrial fibrillation | Milestone Pharmaceuticals Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05410860 | Jun 2022 → Aug 2024 | cardiac rhythm disease | Corxel Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04952610 | Dec 2021 → Apr 2026 | cardiac rhythm disease | Milestone Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04072835 | Sep 2019 → Jan 2023 | cardiac rhythm disease | Milestone Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03635996 | Dec 2018 → Nov 2020 | cardiac rhythm disease | Milestone Pharmaceuticals Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT03464019 | Jun 2018 → Jan 2023 | cardiac rhythm disease | Milestone Pharmaceuticals Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-09-03 | Milestone Pharmaceuticals Inc. | Regulatory Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States milestonepharma.com ↗
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that China’s National Medical Products Administration (NMPA) has approved etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT) in adults. |
| 2026-03-31 | Milestone Pharmaceuticals Inc. | Regulatory Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies milestonepharma.com ↗
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Express Scripts, one of the nation’s largest pharmacy benefit managers, has added CARDAMYST™ (etripamil) nasal spray to its commercial national formularies, effective March 27, 2026. |
| 2026-03-16 | Milestone Pharmaceuticals Inc. | Results Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session milestonepharma.com ↗ |
| 2026-01-06 | Milestone Pharmaceuticals Inc. | Regulatory Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency milestonepharma.com ↗ |
All press releases naming this drug 8 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Etripamil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05763953 ↗ |
| Known as | (-)-MSP-2017 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707312 ↗ |
| Known as | Etripamilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707312 ↗ |
| Known as | MS)-MSP-2017 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707312 ↗ |
| Action | Inhibit | “a short-acting calcium-channel blocker” PMID 30049309 ↗ Jul 2018 |
| Modality | Small molecule | — CHEMBL3707312 ↗ |
| Route | Intranasal | “intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices” NCT02296190 ↗ |